Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Fujisawa Ties Up with Fuji RC for Respiratory Care Devices
March 5, 2001
- Dissolution Test Methods Proposed for 13 Active Ingredients
March 5, 2001
- MIC Receives Applications for Clinical Trials via Toll-free Dial
March 5, 2001
- Nomura Securities Starts Nomura Bio Network
March 5, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 5, 2001
- Novartis: Group Sales Up 10% to CHF 35.8 Bil.
March 5, 2001
- 60% of Manufacturer-hired MRs Are Interested in Contract MRs
March 5, 2001
- Korosho to Present Drug Pricing Reform Policy by Summer
March 5, 2001
- Raloxifene Reduces Risk of Breast Cancer
March 5, 2001
- BULLETIN
March 5, 2001
- Government Takes Measures against Stevens-Johnson Syndrome
March 5, 2001
- PMSB to Increase Awareness of Medical Devices Master File System
March 5, 2001
- Big Internet Influence on Pharma Fields Predicted: Mr Tanimura of So-net M3
February 26, 2001
- Strategies of AdvaMed, EUCOMED for Japan Revealed
February 26, 2001
- Suzuken to Quit Nursing Home Business
February 26, 2001
- OTC NEWS IN BRIEF
February 26, 2001
- BUSINESS NEWS IN BRIEF -2-
February 26, 2001
- Sysmex Expands Its Development Base in Europe
February 26, 2001
- Chuikyo Subcommittee Starts Discussions on Drug Prices
February 26, 2001
- Reorganization to Push New Drugs into Orbit as Soon as Possible: Mr Nakashima of Tanabe
February 26, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…